Publications, Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

June 2022

The FURI Study: Patient Outcomes After Treatment with Oral Ibrexafungerp Based on Prior Antifungal Therapy and Patient Enrollment Criteria

The FURI Study: Patient Outcomes After Treatment with Oral Ibrexafungerp Based on Prior Antifungal Therapy and Patient Enrollment Criteria

Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022

Oral Ibrexafungerp Outcomes in Patients with Invasive Candidiasis and Candidemia from the FURI and CARES Studies

Oral Ibrexafungerp Outcomes in Patients with Invasive Candidiasis and Candidemia from the FURI and CARES Studies

Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022

Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study

Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study

R.S. Siebert, M.D. (Pretoria, South Africa)
ECCMID, April 2022

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)

October 2021

$Outcomes of Oral Ibrexafungerp in Refractory Patients from an Interim Analysis of a Phase 3 Open-Label Study (FURI)$

Outcomes of Oral Ibrexafungerp in Refractory Patients from an Interim Analysis of a Phase 3 Open-Label Study (FURI)

TIMM 2021, October 2021

Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES)

Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES)

TIMM 2021, October 2021

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis (DOVE)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis (DOVE)

September 2021

Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)

Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)

IDWeek, September 2021

Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)

Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)

IDWeek, September 2021

1
2
3
4
5
Next »